Schizophrenia Clinical Trials in Belmont, Massachusetts

7 studies are recruiting for schizophrenia in Belmont, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   McLean Hospital, Belmont, Massachusetts

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

2. Cerebellar Modulation of Cognition in Psychosis

   The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Pa…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   McLean Hospital, Belmont, Massachusetts

   Locations

   2 in total

   Run by

   Mclean Hospital

   See if you can join NCT06107764 on ClinicalTrials.gov

3. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

   The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

   Stage

   Not phased

   Ages

   18 and older

   Site

   Local Institution - 0008, Belmont, Massachusetts

   Locations

   20 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07101094 on ClinicalTrials.gov

4. Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

   The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement …

   Stage

   Not phased

   Ages

   18 to 40

   Site

   McLean Hospital, Belmont, Massachusetts

   Locations

   6 in total

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT06740383 on ClinicalTrials.gov

5. Enhanced Coordinated Specialty Care for Early Psychosis

   The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatm…

   Stage

   Not phased

   Ages

   Any age

   Site

   McLean Hospital OnTrack Clinic, Belmont, Massachusetts

   Locations

   5 in total

   Run by

   Mclean Hospital

   See if you can join NCT06071858 on ClinicalTrials.gov

6. Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

   This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held …

   Stage

   Not phased

   Ages

   18 to 55

   Site

   McLean Hospital, Belmont, Massachusetts

   Run by

   Mclean Hospital

   See if you can join NCT05343598 on ClinicalTrials.gov

7. Study of ALTO-101 in Patients With Schizophrenia

   This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

   Stage

   Phase 2

   Ages

   21 to 55

   Site

   Site 5124, Belmont, Massachusetts

   Locations

   14 in total

   Run by

   Alto Neuroscience

   See if you can join NCT06502964 on ClinicalTrials.gov